Rapid Urine Test Evaluated for Helicobacter Pylori Infection
|
By LabMedica International staff writers Posted on 26 Jun 2014 |

Image: Rapirun Helicobacter pylori Antibody Stick. The urine sample is considered positive when two red bands at the test line and control line (arrows) are observed after 15 minutes and is considered negative when only the control line is observed. The absence of a control line indicates an invalid result (Photo courtesy of Duc T Quach).

Image: The PyloriTek rapid urease test to detect Helicobacter pylori (Photo courtesy of Serim Research Co.).
A rapid urine test based on enzyme-linked immunosorbent assay (ELISA) has been developed for the detection of anti-Helicobacter Pylori antibodies in urine.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Noninvasive Sequencing Test Approaches Invasive Genome Sequencing for Prenatal Screening
Prenatal genetic evaluation guides obstetric care, but standard diagnostics often require invasive procedures that carry risks, stress, and access barriers. Noninvasive prenatal testing (NIPT) has expanded... Read more
Blood-Based Assay Detects HER2 Mutations to Guide NSCLC Treatment
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and a subset of patients harbor HER2 (ERBB2) mutations that may be addressed with precision therapies. These HER2‑mutant tumors... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








